tiprankstipranks
Neurogene (NGNE)
NASDAQ:NGNE
US Market
NGNE
Neurogene
RESEARCH TOOLSreports
Want to see NGNE full AI Analyst Report?

Neurogene (NGNE) Stock News & Sentiment

618 Followers
Analyst Reiterates Buy on Neurogene, Maintains $70 Price Target on Promising NGN-401 Profile and Solid Cash Runway
Premium
Ratings
Analyst Reiterates Buy on Neurogene, Maintains $70 Price Target on Promising NGN-401 Profile and Solid Cash Runway
2d ago
NGNE
Neurogene Maintains Buy Rating as Embolden Trial Progresses and Cash Runway Supports Unchanged $180 Price Target
Premium
Ratings
Neurogene Maintains Buy Rating as Embolden Trial Progresses and Cash Runway Supports Unchanged $180 Price Target
7d ago
NGNE
Is NGNE a Buy, Before Earnings?
Premium
Pre-Earnings
Is NGNE a Buy, Before Earnings?
14d ago
NGNE
Neurogene Expands Leadership Team to Drive NGN-401 Commercialization
Premium
Company Announcements
Neurogene Expands Leadership Team to Drive NGN-401 Commercialization
1M ago
8K
NGNE
Compelling Risk‑Reward in Neurogene’s NGN-401: Differentiated Gene Therapy Approach in Rett Syndrome Supports Buy Rating
Premium
Ratings
Compelling Risk‑Reward in Neurogene’s NGN-401: Differentiated Gene Therapy Approach in Rett Syndrome Supports Buy Rating
1M ago
NGNE
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
Premium
Market News
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
1M ago
UPB
AIOT
Buy Rating Backed by Strong NGN-401 Clinical Progress, De-Risking Efficacy Data, and Solid Cash Runway in Rett Syndrome
Premium
Ratings
Buy Rating Backed by Strong NGN-401 Clinical Progress, De-Risking Efficacy Data, and Solid Cash Runway in Rett Syndrome
2M ago
NGNE
More NGNE News >

NGNE News on the Web

Analyst Reiterates Buy on Neurogene, Maintains $70 Price Target on Promising NGN-401 Profile and Solid Cash Runway
TipRanks News
Bullish
LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY)
TipRanks News
Bullish
Neurogene Maintains Buy Rating as Embolden Trial Progresses and Cash Runway Supports Unchanged $180 Price Target
TipRanks News
Bullish
Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE)
TipRanks News
Bullish
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), CytomX Therapeutics (CTMX)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Neurogene (NGNE) and Stereotaxis (STXS)
TipRanks News
Bullish
Stifel Nicolaus Keeps Their Buy Rating on Neurogene (NGNE)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
NGNE
Sector Average
Media Buzz
This Week3 articles
Weekly Average3.5 articles
News Sentiment
This Week100%
Sector Average77%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is NGNE’s Media Buzz Sentiment?
3 articles about NGNE were published this week. In an average week, 3.5 articles are published.
    What is NGNE’s weekly average amount of articles?
    In an average week, 3.5 articles about NGNE are published.
      What is NGNE’s News Sentiment?
      100% of articles about NGNE were positive this week, compared to its sector average of 77%.
        Healthcare Stocks that are Trending in the News
        DOCSDoximity
        AVAHAveanna Healthcare Holdings
        GOSSGossamer Bio
        CGENCompugen
        RLAYRelay Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week